Celyad Oncology (NASDAQ:CYAD) Stock Price Passes Above 50-Day Moving Average of $1.86

Celyad Oncology SA (NASDAQ:CYADGet Rating)’s share price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.86 and traded as high as $2.55. Celyad Oncology shares last traded at $2.44, with a volume of 228,762 shares.

Celyad Oncology Stock Up 20.2 %

The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.04. The firm’s fifty day moving average is $1.86 and its two-hundred day moving average is $2.28.

Celyad Oncology Company Profile

(Get Rating)

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.

Featured Stories

Want More Great Investing Ideas?

Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.